Timo Möttönen - UTU Research Portal

Timo Möttönen

- Docent,
Faculty of Medicine (University of Turku)

timmot@utu.fi

Publications

2 of 3

Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial (2014)
- Journal of Rheumatology
Rantalaiho V, Kautiainen H, Jarvenpaa S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppanen O, Yli-Kerttula T, Mottonen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M
(A1 Refereed original research article in a scientific journal)
Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACotrial (2014)
- Annals of the Rheumatic Diseases
Vappu Rantalaiho, Hannu Kautiainen, Markku Korpela, Kari Puolakka, Harri Blåfield, Kirsti Ilva, Pekka Hannonen, Marjatta Leirisalo-Repo, Timo Möttönen; for the FIN-RACo Study Group
(B1 Non-refereed article in a scientific journal)
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial (2014)
- Annals of the Rheumatic Diseases
Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppanen O, Mottonen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group
(A1 Refereed original research article in a scientific journal)
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial (2013)
- Annals of the Rheumatic Diseases
Rantalaiho VM, Kautiainen H, Korpela M, Hannonen PJ, Leirisalo-Repo M, Mottonen T
(B1 Non-refereed article in a scientific journal)
Correlation of F-18-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs (2013)
- European Journal of Nuclear Medicine and Molecular Imaging
Roivainen A, Hautaniemi S, Mottonen T, Nuutila P, Oikonen V, Parkkola R, Pricop L, Ress R, Seneca N, Seppanen M, Yli-Kerttula T
(A1 Refereed original research article in a scientific journal)
Decline in work disability caused by early rheumatoid arthritis – results from a nationwide Finnish register, 2000-8 (2013)
- Annals of the Rheumatic Diseases
Rantalaiho VM, Kautiainen H, Jarvenpaa S, Virta L, Pohjolainen T, Korpela M, Mottonen T, Puolakka K
(A1 Refereed original research article in a scientific journal)
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis – 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study) (2013)
- Annals of the Rheumatic Diseases
Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppanen O, Luosujarvi R, Luukkainen R, Karjalainen A, Blafield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Mottonen T
(A1 Refereed original research article in a scientific journal)
Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excllent option in early rheumatoid arthritis (2012)
- Clinical and Experimental Rheumatology
Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T
(A1 Refereed original research article in a scientific journal)
Reumatologipula kriisiyttää erikoisalan (2012)
- Lääkärilehti
Leirisalo-Repo M, Hannonen P, Möttönen T, Karjalainen A, Korpela M, Kauppi M
(D1 Article in a professional journal)
Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with the FIN-RACo combination and single disease-modifying antirheumatic drug strategies (2011)
- Clinical and Experimental Rheumatology
Mustila A, Korpela M, Haapala A-M, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P
(A1 Refereed original research article in a scientific journal)